We are the leader in the design and development of pharmacogenomic (PGx) assays of chemotherapeutics. Our assays are used to guide chemotherapy selection in advanced-stage cancer patients and to simulate clinical trials in Model Based Drug Development. To date, we have developed over 80 PGx assays of the most widely used chemotherapeutic drugs to treat over 85% of cancer patients with solid tumors. Our assays are currently being used in multiple clinical trials and research studies in the U.S and Europe.
For individual patients, our PGx assays are used to guide-chemotherapy selection in gastrointestinal, breast, lung and pediatric cancers. For most patients, we can evaluate a broad range of chemotherapeutic agents using a simple blood test to determine the most effective agents, either alone or in combination, for their treatment.
For biopharmaceutical companies, our assays are used in Model Based Drug Development to simulate clinical trials and develop patient enrichment strategies.
